Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma
Clin. transl. oncol. (Print)
; 18(6): 541-549, jun. 2016. tab, ilus
Artigo
em Inglês
| IBECS
| ID: ibc-152748
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
Aberrations in the PI3K signaling pathway are frequently observed in patients with breast cancer. Because of that, PI3K inhibitors are attractive options for the treatment of breast cancer because PI3K is the most proximal component of the pathway other than receptor tyrosine kinases. Buparlisib is a potent and highly specific oral pan-class I PI3K inhibitor, which is currently under investigation in patients with breast cancer. In this article, we describe the PI3K signaling pathway, the prognostic value of PI3K pathway mutations, as well as the mechanism of action of buparlisib. Lastly, we discuss preliminary results of preclinical and clinical studies showing the efficacy and safety profile of this agent in breast cancer patients (AU)
RESUMEN
No disponible
Buscar no Google
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Prognóstico
/
Neoplasias da Mama
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Fosfatidilinositol 3-Quinases
Tipo de estudo:
Estudo diagnóstico
/
Estudo prognóstico
Limite:
Feminino
/
Humanos
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2016
Tipo de documento:
Artigo
Instituição/País de afiliação:
Centro Integral Oncológico Clara Campal/Spain
/
Hospital Universitario Fundación/Spain
/
Spanish National Cancer Research Centre (CNIO)/Spain